Earning The Right To Say FDA Registered Outsource Facility
This article was originally published in The Pink Sheet Daily
FDA’s welcoming inspections to newly registered 503B “outsourcing” compounding facilities are a harsh first hug for the segment: large recalls and adverse inspection reports continue to be the first notable results from the inspections.
You may also be interested in...
US FDA’s 22nd Patient-Focused Drug Development meeting focused on the challenging disease of autism. It also showed how far FDA has come in embracing the patient-input process over the past five years.
US agency's top neurology review officials received warm reception during Patient Focused Drug Development meeting for Spinal Muscular Atrophy. They also delivered a strong message of continued engagement beyond the first drug approval.
US agency has started transitioning to a new model for Patient-Focused Drug Development meetings, with agency officials attending four externally hosted meetings so far, with at least three more planned for the next few months. So far, the Neurology Products Division has been particularly active with the external meetings.